Don’t Forget To Take A Deeper Look This Summer
Have you heard of cutaneous squamous cell carcinoma, or CSCC? It’s one of the most common types of skin cancer, with about 1 million cases diagnosed in the U.S. every year. When detected early, most cases of local CSCC are easily treated and usually cured. But when they become more advanced, these skin cancers can become dangerous.
During Men’s Health Month and all summer long, we’re urging men and women to be more aware of their skin health by protecting themselves from sun damage—and by getting medical screenings.
Men, It's Time You Took Control of Your Health
By Richard Levin, MHN Advisor
Men generally put off their health issues until something goes wrong, then it’s off to the doctor. Often times it may be a sports injury or even when more serious health issues arrive. Unfortunately, too few men are waiting for the next emergency and it’s having costly repercussions. Men already have lower mortality rates than women dying on average five years sooner. Men are also more likely to die from heart disease, cancer, and diabetes than women.
But men don’t have to wait until their next emergency.
Us men need to step up the bat; we need to be proactive. We owe it to ourselves and our families. Women, on the other hand, tend to be more aware of not just their health but the health of their families, including men. Still, the modern healthcare system has processes in place to keep women engaged through things like annual Well-Woman exams that can include mammograms and Pap smears. Comprehensive, and branded check-up like that don’t exist for men, which is why it’s important for men to become their own health advocates and take control of their health.
FDA Approves New Drug For Men Battling Non-Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc. and Pfizer Inc. recently announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide), following FDA Priority Review designation, based on results from the Phase 3 PROSPER trial. The FDA action broadens the indication for XTANDI to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
This approval makes XTANDI the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC. XTANDI was first approved by the FDA in 2012 for the treatment of patients with metastatic CRPC who had previously received docetaxel, and was granted approval in 2014 for chemotherapy-naïve men with metastatic CRPC